Protein arginine methyltransferase 5 (PRMT5) is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer.

MLA

Lin, Chang-Ching, et al. “Protein Arginine Methyltransferase 5 (PRMT5) Is an Actionable Therapeutic Target in CDK4/6 Inhibitor-Resistant ER+/RB-Deficient Breast Cancer.” Research Square, July 2023. EBSCOhost, https://doi.org/10.21203/rs.3.rs-2966905/v1.

APA

Lin, C.-C., Chang, T.-C., Wang, Y., Guo, L., Gao, Y., Bikorimana, E., Lemoff, A., Fang, Y. V., Zhang, H., Zhang, Y., Ye, D., Soria-Bretones, I., Servetto, A., Lee, K.-M., Luo, X., Otto, J. J., Akamatsu, H., Napolitano, F., Mani, R., … Arteaga, C. L. (2023). Protein arginine methyltransferase 5 (PRMT5) is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer. Research Square. https://doi.org/10.21203/rs.3.rs-2966905/v1

Chicago

Lin, Chang-Ching, Tsung-Cheng Chang, Yunguan Wang, Lei Guo, Yunpeng Gao, Emmanuel Bikorimana, Andrew Lemoff, et al. 2023. “Protein Arginine Methyltransferase 5 (PRMT5) Is an Actionable Therapeutic Target in CDK4/6 Inhibitor-Resistant ER+/RB-Deficient Breast Cancer.” Research Square, July. doi:10.21203/rs.3.rs-2966905/v1.